Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Pembrolizumab in Recurrent Advanced Melanoma
NCT04768881Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in melanoma (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall Response Rate up to 24 months. Started May 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04768881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768881.